Article
Bristol Myers sales fall, cuts 2023 forecast as drugs face competition
Rating:
0.0
Views:
74
Likes:
1
Library:
1
Bristol Myers Squibb on Thursday said its second-quarter sales fell more than expected and cut its full-year forecasts as two of its top drugs, the blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value